LOSMAPIMOD ( DrugBank: Losmapimod )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
113	筋ジストロフィー	7
222	一次性ネフローゼ症候群	1

113. 筋ジストロフィー

臨床試験数 : 646 / 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170

diseases per page:

Showing 1 to 7 of 7 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2022-000389-16-ES (EUCTR)	14/07/2022	15/07/2022	A Phase 3 study to determine the Efficacy and Safety of LosmapimodinTreating Patients with Facioscap ...	A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the ...	Facioscapulohumeral Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 10064087;T ...	Product Name: Losmapimod Product Code: FTX-1821 INN or Proposed INN: Losmapimod	Fulcrum Therapeutics	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	230	Phase 3	France;United States;Canada;Spain;Denmark;Germany;Netherlands;United Kingdom;Italy
2	NCT05397470 (ClinicalTrials.gov)	June 16, 2022	4/5/2022	Efficacy and Safety of Losmapimodin Treating Patients With Facioscapulohumeral Muscular Dystrophy (F ...	A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the ...	Facioscapulohumeral Muscular Dystrophy (FSHD)	Drug: Losmapimod;Drug: Placebo oral tablet	Fulcrum Therapeutics	NULL	Recruiting	18 Years	65 Years	All	230	Phase 3	United States;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom
3	NCT04264442 (ClinicalTrials.gov)	February 13, 2020	30/1/2020	Efficacy and Safety of Losmapimodin Treating Subjects With Facioscapulohumeral Muscular Dystrophy (F ...	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the Effica ...	Facioscapulohumeral Muscular Dystrophy (FSHD)	Drug: Losmapimod	Fulcrum Therapeutics	NULL	Active, not recruiting	18 Years	65 Years	All	76	Phase 2	United States;Canada;France;Spain;Germany
4	EUCTR2019-001181-15-ES (EUCTR)	29/10/2019	29/10/2019	Safety and Efficacy of Losmapimod in Patients with FSHD	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 24-Week, Parallel-Group Study of the Effica ...	Facioscapulohumeral Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 10064087;T ...	Product Name: Losmapimod Product Code: FTX-1821 INN or Proposed INN: LOSMAPIMOD	Fulcrum Therapeutics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	66	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	France;United States;Spain;Germany
5	EUCTR2019-001181-15-FR (EUCTR)	17/09/2019	29/05/2019	Safety and Efficacy of Losmapimod in Patients with FSHD	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 24-Week, Parallel-Group Study of the Effica ...	Facioscapulohumeral Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 10064087;T ...	Product Name: Losmapimod Product Code: FTX-1821 INN or Proposed INN: LOSMAPIMOD	Fulcrum Therapeutics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	66	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	United States;France;Spain;Germany
6	NCT04004000 (ClinicalTrials.gov)	August 23, 2019	25/6/2019	Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Los ...	An Open-Label Pilot Study of Losmapimodto Evaluate the Safety, Tolerability, and Changes in Biomarke ...	Facioscapulohumeral Muscular Dystrophy 1	Drug: Losmapimod	Fulcrum Therapeutics	NULL	Active, not recruiting	18 Years	65 Years	All	14	Phase 2	Netherlands
7	NCT04003974 (ClinicalTrials.gov)	August 9, 2019	25/6/2019	Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the Effica ...	Facioscapulohumeral Muscular Dystrophy (FSHD)	Drug: Losmapimod;Drug: Placebo oral tablet	Fulcrum Therapeutics	NULL	Completed	18 Years	65 Years	All	80	Phase 2	United States;Canada;France;Spain;Germany

First Previous1Next Last

先頭へ

222. 一次性ネフローゼ症候群

臨床試験数 : 310 / 薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02000440 (ClinicalTrials.gov)	July 1, 2014	27/11/2013	A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimodto Reduce Proteinuria in Patients Wit ...	Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)	Glomerulosclerosis, Focal Segmental	Drug: Losmapimod	GlaxoSmithKline	NULL	Completed	18 Years	70 Years	All	17	Phase 2	United States;Canada

First Previous1Next Last

先頭へ